drugset / Trial / NCT05054530
Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106
RandomizedSequentialQuadruple-blindBasic science
Summary
This will be a single centre, Phase 1, placebo-control, randomized, double-blind, sequential single and multiple ascending dose study to assess the safety, tolerability, and PK of GMA106 in healthy, overweight or obese subjects.
Timeline
- Start
- 2021-11-11
- Primary completion
- 2023-11-17
- Completion
- 2023-11-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GMA106 | Unknown | 20 mg | Subcutaneous |
| Subject | GMA106 | Unknown | 40 mg | Subcutaneous |
| Subject | GMA106 | Unknown | 80 mg | Subcutaneous |
Indications
No indication recorded.